Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Eli Lilly and Company's quarterly P/E stands at 27.8x, down 58.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 30.6% YoY to 23.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 43.06 | 27.84 | 36.36 | 30.72 | 30.98 | 67.48 | 39.55 | 207.00 | 69.01 | 78.42 | 60.22 | — | 63.03 |
| — | -58.7% | -8.1% | -85.2% | -55.1% | -14.0% | -34.3% | — | +9.5% | +29.7% | +34.3% | — | -18.3% | |
| P/S Ratio | 14.32 | 10.40 | 12.51 | 9.74 | 11.27 | 14.61 | 12.88 | 17.52 | 18.11 | 20.05 | 14.08 | 13.42 | 13.39 |
| — | -28.8% | -2.9% | -44.4% | -37.8% | -27.1% | -8.5% | +30.6% | +35.2% | +71.2% | +18.3% | +27.5% | +18.7% | |
| P/B Ratio | 33.44 | 26.41 | 36.37 | 28.75 | 38.23 | 46.94 | 48.85 | 55.99 | 60.04 | 54.52 | 48.51 | 45.09 | 39.93 |
| — | -43.7% | -25.6% | -48.6% | -36.3% | -13.9% | +0.7% | +24.2% | +50.4% | +88.9% | +50.4% | +56.9% | +18.1% | |
| P/FCF | 104.06 | 68.51 | 355.90 | 19.91 | 136.67 | — | 239.90 | — | 3228.09 | 978.19 | — | — | — |
| — | — | +48.4% | — | -95.8% | — | — | — | — | +892.7% | — | — | — | |
| EV / EBITDA | 31.00 | 23.03 | 28.01 | 20.28 | 24.26 | 33.18 | 28.95 | 41.34 | 43.68 | 57.94 | 38.35 | 33.38 | 42.64 |
| — | -30.6% | -3.2% | -50.9% | -44.5% | -42.7% | -24.5% | +23.8% | +2.4% | +41.0% | +9.5% | +4.9% | +16.3% | |
| EV / EBIT | 32.63 | 24.35 | 30.37 | 24.23 | 26.26 | 52.65 | 34.56 | 116.43 | 57.04 | 66.91 | 51.88 | 239.08 | 52.20 |
| — | -53.7% | -12.1% | -79.2% | -54.0% | -21.3% | -33.4% | -51.3% | +9.3% | +28.0% | +25.1% | +415.5% | -20.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Eli Lilly and Company's operating margin was 44.7% in Q1 2026, down 0.8 pp QoQ and up 2.2 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 45.9% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 81.9% | 85.1% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | 80.4% | 78.3% |
| — | -0.7% | +3.4% | +2.3% | +4.3% | +2.0% | +1.7% | +0.8% | +3.3% | +5.6% | +2.6% | +4.1% | +0.4% | |
| Operating Margin | 45.6% | 44.7% | 45.5% | 47.6% | 45.8% | 42.5% | 42.8% | 39.8% | 39.1% | 31.2% | 34.1% | 37.3% | 28.1% |
| — | +5.2% | +6.2% | +19.8% | +17.2% | +36.2% | +25.5% | +6.7% | +39.0% | +26.6% | +12.9% | +27.0% | +4.6% | |
| Net Margin | 31.7% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% | 23.4% | -0.6% | 21.2% |
| — | +72.3% | +5.6% | +273.9% | +38.6% | -15.3% | +39.2% | +1503.7% | +23.7% | +32.4% | -11.8% | -102.9% | +44.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 101.2% | 25.6% | 26.3% | 26.5% | 33.1% | 18.3% | 30.8% | 6.9% | 22.4% | 18.9% | 19.8% | -0.5% | 15.7% |
| — | +39.8% | -14.6% | +281.1% | +48.0% | -2.9% | +56.2% | +1457.9% | +42.3% | +54.9% | +6.7% | -103.3% | +49.5% | |
| ROA | 21.6% | 6.5% | 5.8% | 5.2% | 5.9% | 3.3% | 5.7% | 1.3% | 4.4% | 3.5% | 3.6% | -0.1% | 3.3% |
| — | +96.7% | +2.1% | +293.1% | +36.2% | -6.4% | +59.1% | +1392.5% | +33.8% | +33.8% | -10.1% | -103.3% | +61.1% | |
| ROIC | 41.8% | 10.1% | 11.1% | 11.3% | 10.1% | 8.5% | 10.0% | 8.4% | 8.7% | 5.9% | 7.7% | 9.4% | 6.5% |
| — | +19.7% | +10.8% | +34.6% | +15.4% | +44.1% | +30.6% | -11.0% | +34.1% | +17.7% | +12.2% | +42.7% | +15.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Eli Lilly and Company's Debt/EBITDA ratio is 4.6x — elevated, raising questions about debt serviceability. The current ratio has improved 9.1% YoY to 1.50x, strengthening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.60 | 1.39 | 1.60 | 1.78 | 2.17 | 2.43 | 2.36 | 2.17 | 2.12 | 2.03 | 2.32 | 1.78 | 1.69 |
| — | -42.8% | -32.1% | -18.0% | +2.6% | +19.6% | +1.5% | +21.8% | +25.5% | +21.6% | +54.1% | +14.1% | -13.1% | |
| Debt / EBITDA | 1.36 | 4.63 | 4.76 | 4.80 | 5.25 | 6.56 | 5.36 | 6.20 | 5.98 | 8.36 | 7.04 | 5.10 | 6.96 |
| — | -29.4% | -11.1% | -22.6% | -12.2% | -21.5% | -24.0% | +21.6% | -14.1% | -8.1% | +12.0% | -22.9% | -13.4% | |
| Current Ratio | 1.58 | 1.50 | 1.58 | 1.55 | 1.28 | 1.37 | 1.15 | 1.27 | 1.11 | 1.35 | 0.94 | 1.05 | 1.13 |
| — | +9.1% | +36.9% | +21.5% | +14.7% | +1.3% | +22.4% | +21.7% | -1.2% | +4.2% | -10.4% | -7.2% | +2.9% | |
| Quick Ratio | 1.19 | 1.10 | 1.19 | 1.24 | 1.00 | 1.06 | 0.89 | 0.97 | 0.87 | 1.03 | 0.73 | 0.82 | 0.87 |
| — | +3.5% | +34.1% | +28.0% | +13.8% | +3.5% | +21.2% | +18.0% | +0.1% | +1.0% | -8.7% | -6.7% | +3.3% | |
| Interest Coverage | 33.16 | 26.66 | 66.96 | 41.27 | 28.21 | 15.18 | 23.42 | 9.24 | 20.16 | 15.12 | 19.15 | 4.43 | 18.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying LLY stock.
Eli Lilly and Company's current P/E is 43.1x. The average P/E over the last 4 quarters is 31.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Eli Lilly and Company's current operating margin is 45.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Eli Lilly and Company's business trajectory between earnings reports.